title: [Cardiovascular risk stratification in general practice].
abstract: The ESC risk charts are helpful to identify high risk patients in general practice who are candidates for preventive treatment. The use of the ESC charts is one important step to initiate "evidence based medicine" in the daily practice of preventive cardiology.Cardiovascular diseases are the most important causes of premature disability and death in Germany. High risk patients however are frequently not recognized. A systematic risk stratification in general practice could identify high risk persons and allow a cost effective treatment approach. The goal of the CAD-scoring week was to identify high risk persons with the use of the ESC risk charts and to evaluate the treatment resulting from risk stratification. In addition the feasibility of the risk charts in daily office routine was to be evaluated. A total of 1122 of 20 000 (5.6%) contacted general physicians agreed to participate in the screening procedure. More than 27 000 patients (> 50 yrs) were evaluated using the ESC risk charts. 21.6% of women (n = 15 018) vs 22.2%* of men (n = 12 361) had markedly elevated blood pressure (> 150 mmHg), 29 vs. 24%* had a total cholesterol > 250 mg/dl (6.5 mmol/l), 25.5 vs 29.9%* smoked and 28.4 vs. 31.9%* had diabetes (*female vs male: p < 0.0003). Altogether 19.4% of women vs. 53% of men were newly identified as high risk patients (risk > 20% in 10 years). More than 40% of these high risk patients received drug treatment for prevention (ASA, lipid lowering drugs or ACE inhibitors). More than 70% of the participating physicians judged the risk charts to be helpful in patient management.
authors.affiliation: Klinische Kardiologie II, Herz-Zentrum Bad Krozingen, Südring 15, 79189 Bad Krozingen, Germany.
authors.forename: H
authors.initials: H
authors.lastname: Gohlke
authors.forename: A
authors.initials: A
authors.lastname: Schirmer
authors.forename: K-H
authors.initials: KH
authors.lastname: Theobald
mesh_terms: D000328:Adult; D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D001794:Blood Pressure / Q000502:physiology; D002784:Cholesterol / Q000097:blood; D003324:Coronary Artery Disease / Q000145:classification / Q000453:epidemiology* / Q000209:etiology / Q000401:mortality; D048909:Diabetes Complications; D003920:Diabetes Mellitus / Q000453:epidemiology; D005194:Family Practice; D005260:Female; D005858:Germany; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009098:Multiphasic Screening; D015203:Reproducibility of Results; D018570:Risk Assessment / Q000706:statistics & numerical data; D012907:Smoking / Q000009:adverse effects; D015996:Survival Rate
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D000960:Hypolipidemic Agents; D002784:Cholesterol; D001241:Aspirin